 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
How Long Should Blood Thinners Be Given to Patients Who Have Had a Pulmonary Embolism?
1 July 2003 | Volume 139 Issue 1 | Page I-51
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism." It is in the 1 July 2003 issue of Annals of Internal Medicine (volume 139, pages 19-25). The authors are G. Agnelli, P. Prandoni, C. Becattini, M. Silingardi, M.R. Taliani, M. Miccio, D. Imberti, R. Poggio, W. Ageno, E. Pogliani, F. Porro, and P. Zonzin, for the Warfarin Optimal Duration Italian Trial Investigators.
What is the problem and what is known about it so far?
Blood clots sometimes form in leg veins and then break loose. When they travel to the lungs, they can cause serious or fatal consequences. The process of clot formation and breakaway is called thromboembolism, and blood clots that reach the lungs cause pulmonary embolism. Doctors can treat these problems with blood thinners. People who have had one pulmonary embolism are at increased risk for recurrent thromboembolism. The likelihood of recurrence depends on whether there is a transient problem that promotes clot formation (such as leg trauma) or no recognizable inciting event. Despite their effectiveness, blood thinners can also cause dangerous bleeding, so doctors prefer to treat patients with pulmonary embolism as briefly as possible. No one knows the safest treatment duration for a first pulmonary embolism, but doctors often give treatment for 3 months in patients with short-term risk factors and 6 months in those without known risk factors.
Why did the researchers do this particular study?
To find out if patients with a first pulmonary embolism benefited from extending blood-thinning therapy to 6 months (those with short-term risk factors) and to 1 year (those without known risk factors).
Who was studied?
326 patients who had completed 3 months of blood-thinning therapy for pulmonary embolism but had not experienced a recurrence or an episode of bleeding were included in the study. 145 of the patients had short-term risk factors for pulmonary embolism and 181 patients had no known risk factor.
How was the study done?
The researchers randomly assigned study participants to either stop blood thinners immediately or continue therapy (for an additional 3 months for those with short-term risk factors or 9 months for those with no known risk factors). They followed all participants to detect symptoms of recurrent pulmonary embolism and tested the suspected cases to confirm the diagnosis. They also recorded any episodes of major bleeding or other complications. Study participants returned for follow-up 3, 6, and 12 months after they entered the study and then every 6 months until the study was complete.
What did the researchers find?
33 patients had recurrent thromboembolic disease, but only one of these episodes occurred while the patient was still receiving blood thinners. Once blood thinners were stopped, patients who had received extended therapy were just as likely to develop thromboembolism as those who received shortened therapy. Complications were similar in both the groups.
What were the limitations of the study?
Since both patients and doctors knew the treatment group assignments, more tests may have been done to confirm recurrence in one group than the other.
What are the implications of the study?
Extended treatment with blood thinners does not seem to protect against recurrence once therapy has been discontinued. Patients at high risk for recurrence may best be treated by continuing blood thinners indefinitely.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. Verhovsek, J. D. Douketis, Q. Yi, S. Shrivastava, R. C. Tait, T. Baglin, D. Poli, and W. Lim Systematic Review: D-Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism Ann Intern Med, October 7, 2008; 149(7): 481 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H White Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous thromboembolism Evid. Based Med., October 1, 2008; 13(5): 154 - 154. [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, A. Torbicki, A. Perrier, S. Konstantinides, G. Agnelli, N. Galie, P. Pruszczyk, F. Bengel, A. J.B. Brady, D. Ferreira, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur. Heart J., September 2, 2008; 29(18): 2276 - 2315. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Rodger MD MSc, S. R. Kahn MD MSc, P. S. Wells MD MSc, D. A. Anderson MD, I. Chagnon MD, G. Le Gal MD PhD, S. Solymoss MD, M. Crowther MD, A. Perrier MD, R. White MD, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy Can. Med. Assoc. J., August 26, 2008; 179(5): 417 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Legnani, G. Palareti, B. Cosmi, M. Cini, A. Tosetto, A. Tripodi, and for the PROLONG Investigators (on behalf of FCSA a Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study Haematologica, June 1, 2008; 93(6): 900 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 257S - 298S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 454S - 545S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The van Gogh Investigators Extended Prophylaxis of Venous Thromboembolism with Idraparinux N. Engl. J. Med., September 13, 2007; 357(11): 1105 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W Eikelboom, J. S Ginsberg, and J. Hirsh Anticoagulation for venous thromboembolism BMJ, March 31, 2007; 334(7595): 645 - 645. [Full Text] [PDF]
|
|
|
|
|
|
I A Campbell, D P Bentley, R J Prescott, P A Routledge, H G M Shetty, and I J Williamson Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial BMJ, March 31, 2007; 334(7595): 674 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Segal, M. B. Streiff, L. V. Hofmann, K. Thornton, and E. B. Bass Management of Venous Thromboembolism: A Systematic Review for a Practice Guideline Ann Intern Med, February 6, 2007; 146(3): 211 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Prandoni, F. Noventa, A. Ghirarduzzi, V. Pengo, E. Bernardi, R. Pesavento, M. Iotti, D. Tormene, P. Simioni, and A. Pagnan The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients Haematologica, February 1, 2007; 92(2): 199 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Snow, A. Qaseem, P. Barry, E. R. Hornbake, J. E. Rodnick, T. Tobolic, B. Ireland, J. Segal, E. Bass, K. B. Weiss, et al. Management of Venous Thromboembolism: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians Ann. Fam. Med, January 1, 2007; 5(1): 74 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Grifoni, S. Vanni, S. Magazzini, I. Olivotto, A. Conti, M. Zanobetti, G. Polidori, F. Pieralli, N. Peiman, C. Becattini, et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med, October 23, 2006; 166(19): 2151 - 2156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Miller, I. Campbell, T. Fennerty, G. E. Raskob, and H. R. Buller Duration of warfarin in pulmonary embolism. Chest, July 1, 2006; 130(1): 299 - 300. [Full Text] [PDF]
|
|
|
|
 |
|
 P. de Moerloose, C. M. Samama, and S. Motte Management of venous thromboembolism: [Traitement de la maladie thromboembolique veineuse]. Can J Anesth, June 1, 2006; 53(6_suppl): S80 - S88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Bockenstedt Management of Hereditary Hypercoagulable Disorders Hematology, January 1, 2006; 2006(1): 444 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Aujesky, K. J. Smith, J. Cornuz, and M. S. Roberts Cost-Effectiveness of Low-Molecular-Weight Heparin for Treatment of Pulmonary Embolism Chest, September 1, 2005; 128(3): 1601 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ost, J. Tepper, H. Mihara, O. Lander, R. Heinzer, and A. Fein Duration of Anticoagulation Following Venous Thromboembolism: A Meta-analysis JAMA, August 10, 2005; 294(6): 706 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Becattini, G. Agnelli, P. Prandoni, M. Silingardi, R. Salvi, M. R. Taliani, R. Poggio, D. Imberti, W. Ageno, E. Pogliani, et al. A prospective study on cardiovascular events after acute pulmonary embolism Eur. Heart J., January 1, 2005; 26(1): 77 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Z. Goldhaber Prevention of Recurrent Idiopathic Venous Thromboembolism Circulation, December 14, 2004; 110(24_suppl_1): IV-20 - IV-24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Agnelli, C. Becattini, P. Prandoni, J. A. Nieto, M. Monreal, the RIETE Investigators, S. R. Kahn, B. Boari, R. Salmi, R. Manfredini, et al. Recurrent Venous Thromboembolism in Men and Women N. Engl. J. Med., November 4, 2004; 351(19): 2015 - 2018. [Full Text] [PDF]
|
|
|
|
|
|
M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 287S - 310S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Buller, G. Agnelli, R. D. Hull, T. M. Hyers, M. H. Prins, and G. E. Raskob Antithrombotic Therapy for Venous Thromboembolic Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 401S - 428S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kearon Long-Term Management of Patients After Venous Thromboembolism Circulation, August 31, 2004; 110(9_suppl_1): I-10 - I-18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Weitz New Anticoagulants for Treatment of Venous Thromboembolism Circulation, August 31, 2004; 110(9_suppl_1): I-19 - I-26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wan, D. J. Quinlan, G. Agnelli, and J. W. Eikelboom Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism: A Meta-Analysis of the Randomized Controlled Trials Circulation, August 10, 2004; 110(6): 744 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted: 25 Jul 03 to 7 Nov 03 Evid. Based Nurs., January 1, 2004; 7(1): e1 - 1. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Lopez, C. Kearon, and A. Y.Y. Lee Deep Venous Thrombosis Hematology, January 1, 2004; 2004(1): 439 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Z. Goldhaber and C. G. Elliott Acute Pulmonary Embolism: Part II: Risk Stratification, Treatment, and Prevention Circulation, December 9, 2003; 108(23): 2834 - 2838. [Full Text] [PDF]
|
|
|
|
|
|
L.-A. Linkins, P. T. Choi, and J. D. Douketis Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-Analysis Ann Intern Med, December 2, 2003; 139(11): 893 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Duration of Oral Anticoagulation Therapy After a First PE Journal Watch Cardiology, September 12, 2003; 2003(912): 2 - 2. [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
